Tumor Treating Fields (TTFields)

DEVICE2 trials

Sponsors

Tel Aviv Medical Center, Prof. Franciszek Lukaszczyk Memorial Oncology Center

Conditions

GBMGlioblastomaGlioblastoma IDH (Isocitrate Dehydrogenase) WildtypeGlioblastoma Multiforme, Adult

Phase 1

Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma

WithdrawnNCT05973903

Tel Aviv Medical CenterGBM

Start: 2024-06-01End: 2027-10-01Updated: 2024-12-04

Unknown Phase

TTFields Plus FET-PET-Guided Stereotactic Radiosurgery Versus TTFields Alone for Recurrent Glioblastoma (Tarrget 2.0)

RecruitingNCT07668869

Prof. Franciszek Lukaszczyk Memorial Oncology CenterGlioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Glioblastoma Multiforme, Adult

Start: 2025-12-30End: 2032-06-01Target: 92Updated: 2026-06-25